Market Update: Gilead Sciences Inc (NASDAQ:GILD) – India rejects Gilead’s Hepatitis C drug patent request

[Reuters] – India’s patent office has rejected an application from U.S.-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drugmakers to launch cheaper generic versions of the . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – India rejects Gilead’s Hepatitis C drug patent request Similar Articles: Market Update (NASDAQ:GILD): UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor